Maxim upgraded Virpax Pharmaceuticals to Buy from Hold with a $3 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRPX:
- Virpax announces positive results of Swine Model pilot study for Probudur
- Virpax Pharmaceuticals’ Strategic Financing and Board Reshaping
- Virpax announces $2.5M loan financing, additional pact with investor
- Virpax Pharmaceuticals downgraded to Hold at Maxim on capital constraints
- Virpax Pharmaceuticals downgraded to Hold from Buy at Maxim